Sarcoma treatment in the era of molecular medicine

Grünewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F, Di Pompo G, Distel M, Dorado-Garcia H, Garcia-Castro J, González-González L, Grigoriadis AE, Kasan M, Koelsche C, Krumbholz M, Lecanda F, Lemma S, Longo DL, Madrigal-Esquivel C, Morales-Molina Á, Musa J, Ohmura S, Ory B, Pereira-Silva M, Perut F, Rodriguez R, Seeling C, Al Shaaili N, Shaabani S, Shiavone K, Sinha S, Tomazou EM, Trautmann M, Vela M, Versleijen-Jonkers YM, Visgauss J, Zalacain M, Schober SJ, Lissat A, English WR, Baldini N, Heymann D (2020)

Publication Type: Journal article, Review article

Publication year: 2020

Journal

DOI: 10.15252/emmm.201911131

Abstract

Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult-to-treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.

Authors with CRIS profile

Involved external institutions

Ludwig-Maximilians-Universität (LMU) Germany (DE) Universidad de Navarra Spain (ES) Rizzoli Orthopaedic Institute / Istituto Ortopedico Rizzoli (IRCCS) Italy (IT) Deutsches Krebsforschungszentrum (DKFZ) Germany (DE) Technische Universität München (TUM) Germany (DE) St. Anna Kinderkrebsforschung Austria (AT) Charité - Universitätsmedizin Berlin Germany (DE) Instituto de Salud Carlos III (Institute of Health Carlos III, ISCIII) Spain (ES) King’s College London United Kingdom (GB) Universitätsklinikum Heidelberg Germany (DE) Consiglio Nazionale delle Ricerche (CNR) / National Research Council of Italy Italy (IT) University of Sheffield United Kingdom (GB) Université de Nantes France (FR) Universidade de Coimbra Portugal (PT) ISPA Instituto de Investigación Sanitaria del Principado de Asturias Spain (ES) Universität Ulm Germany (DE) University of Groningen / Rijksuniversiteit Groningen Netherlands (NL) Helsingin yliopisto / University of Helsinki Finland (FI) Universitätsklinikum Münster Germany (DE) Hospital Universitario La Paz Spain (ES) Radboud University Nijmegen Medical Centre / Radboudumc of voluit Radboud Universitair Medisch Centrum (UMC) Netherlands (NL) Duke University United States (USA) (US) Universitäts-Kinderspital Zürich Switzerland (CH)

How to cite

APA:

Grünewald, T.G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre-Aranaz, F.,... Heymann, D. (2020). Sarcoma treatment in the era of molecular medicine. Embo Molecular Medicine. https://doi.org/10.15252/emmm.201911131

MLA:

Grünewald, Thomas G.P., et al. "Sarcoma treatment in the era of molecular medicine." Embo Molecular Medicine (2020).

BibTeX: Download